RESEARCH TRIANGLE PARK, N.C., Oct. 1, 2026 — TruTechnologies (Tru), the industry’s first Live Clinical Trial Execution platform, is pleased to share local momentum within the Triangle as it advances its mission to redefine the speed and reliability of clinical trials. This year has marked widespread industry fervor to address the longstanding issues in clinical trial execution that hold back pharmaceutical innovation. From the FDA’s real-time clinical trials pilot program and HHS’s Operation TrialBlazer to promises of AI’s potential to bring effective drugs to patients quicker, stakeholders are demanding change and Tru’s technology is purpose-built to deliver it.
Amidst this industry velocity, Tru has been named one of Triangle Business Journal’s 2026 Fast 50 winners and a finalist in the Biotech + HealthTech Innovation category of the 2026 NC TECH Awards. Tru’s CEO and co-founder Scott Ogle will also join the “Future of Healthcare Innovation” panel at the Raleigh Chamber’s Healthcare Summit this fall.
Triangle Business Journal Fast 50 Winner: In the 34th year of its Fast 50 awards, Triangle Business Journal selected Tru as one of the Triangle’s fastest-growing private companies based on its growth over the past three years. The awards recognize winners for not only their success, but their contribution to creating local jobs and economic activity. The company’s ranking will be revealed at the Fast 50 awards event on October 21.
NC Tech Awards Finalist: Tru has been named a finalist in the Biotech + HealthTech Innovation category of the 2026 NC TECH Awards, which recognize innovation, growth and leadership across North Carolina’s technology sector. Winners will be announced live at the NC TECH Awards Celebration in Durham on November 16.
Tru’s CEO Joins Raleigh Chamber’s Healthcare Summit: CEO and co-founder Scott Ogle will join the “Future of Healthcare Innovation” panel at the Greater Raleigh Chamber’s Healthcare Summit on November 6. He will bring a clinical trial execution perspective to the discussion, and looks forward to sharing his take on AI’s role in the space, which he believes should be viewed as a strategic layer applied to verified data, not the foundation for next-era trial delivery.
“We are so proud to receive these recent recognitions within the Triangle, as the region is the country’s preeminent home of innovation within the life sciences,” said Scott Ogle, CEO and co-founder of TruTechnologies. “As we continue to further our mission to bring truth to every trial, we are eager to continue to collaborate and hire locally, with other like-minded innovators determined to modernize our dated clinical trial execution system.”
Tru’s recent momentum comes on the heels of its recently announced rebrand. Those interested to join Tru’s team are encouraged to explore open careers here.
About TruTechnologies
TruTechnologies is the industry’s first Live Clinical Trial Execution platform, redefining the speed and reliability of clinical trials. Tru combines dynamic, protocol-guided workflows, Live Data Capture™, and instant sponsor visibility to help teams prevent deviations and surface risks earlier, so therapies reach patients sooner. Trusted by leading pharma companies and deployed across 3,300+ sites in 60 countries, Tru delivers real-world partnership and proven results. Because when clinical trials succeed, patients win.